Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) announced on Tuesday the launch of Baclofen Oral Suspension, a generic alternative to Fleqsuvy.
Baclofen Oral Suspension is a treatment for spasticity from multiple sclerosis or spinal cord injuries and other spinal cord diseases. Fleqsuvy is marketed by Azurity Pharmaceuticals Inc.
Total US annual sales for Baclofen Oral Suspension amount to approximately USD39m, according to IQVIA data.
Biocon seeking partner to test semaglutide generics in China
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
ANI Pharmaceuticals launches generic Baclofen Oral Suspension
Mikart adds Fette double-sided tablet presses
Biocon Biologics enters five-year partnership with Sandoz Australia
Mallinckrodt names new directors
Rottendorf Pharma enhances operations with Rockwell Automation's FactoryTalk PharmaSuite MES